Buying Opportunity • Apr 21
Now 22% undervalued Over the last 90 days, the stock is up 4.2%. The fair value is estimated to be UK£17.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 35% per annum over the same time period. Recent Insider Transactions • Apr 09
Key Executive recently bought UK£67k worth of stock On the 4th of April, Peter Allen bought around 5k shares on-market at roughly UK£14.36 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months. Major Estimate Revision • Mar 21
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from UK£0.20 to UK£0.16 per share. Revenue forecast steady at UK£378.0m. Net income forecast to grow 708% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target down from UK£15.70 to UK£15.27. Share price rose 8.4% to UK£13.59 over the past week. Reported Earnings • Mar 15
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: UK£0.019 (up from UK£0.009 loss in FY 2020). Revenue: UK£315.4m (up 17% from FY 2020). Net income: UK£4.40m (up UK£6.30m from FY 2020). Profit margin: 1.4% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 66%. Over the next year, revenue is forecast to grow 19%, compared to a 20% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Mar 08
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.07 to UK£0.06 per share. Revenue forecast steady at UK£313.9m. Net income forecast to grow 75% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target of UK£15.71 unchanged from last update. Share price fell 4.9% to UK£11.71 over the past week. Major Estimate Revision • Jan 07
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.10 to UK£0.09 per share. Revenue forecast steady at UK£317.0m. Net income forecast to grow 147% next year vs 7.0% growth forecast for Biotechs industry in the United Kingdom. Consensus price target up from UK£14.89 to UK£15.21. Share price fell 12% to UK£15.28 over the past week. Recent Insider Transactions Derivative • Nov 12
CEO & Executive Director exercised options and sold UK£926k worth of stock On the 8th of November, Alan Hirzel exercised options to acquire 55k shares at no cost and sold these for an average price of UK£16.89 per share. This trade did not impact their existing holding. For the year to June 2020, Alan's total compensation was 39% salary and 61% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Alan's direct individual holding has increased from 214.87k shares to 221.76k. Company insiders have collectively sold UK£1.1m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Sep 26
CEO & Executive Director recently sold UK£94k worth of stock On the 23rd of September, Alan Hirzel sold around 6k shares on-market at roughly UK£15.36 per share. This was the largest sale by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months. Reported Earnings • Sep 15
Full year 2021 earnings released: EPS UK£0.073 (vs UK£0.06 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£297.7m (up 14% from FY 2020). Net income: UK£16.2m (up 30% from FY 2020). Profit margin: 5.4% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Independent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Executive Departure • May 27
Senior Independent Director has left the company On the 19th of May, Louise A. V. Patten's tenure as Senior Independent Director ended after 6.5 years in the role. As of March 2021, Louise A. V. personally held 54.84k shares (UK£763k worth at the time). Louise A. V. is the only executive to leave the company over the last 12 months. Reported Earnings • Mar 10
First half 2021 earnings released: EPS UK£0.053 (vs UK£0.13 in 1H 2020) The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£147.5m (up 6.7% from 1H 2020). Net income: UK£11.7m (down 55% from 1H 2020). Profit margin: 7.9% (down from 19% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 09
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 18%, compared to a 44% growth forecast for the Biotechs industry in the United Kingdom. Price Target Changed • Feb 22
Price target raised to UK£14.14 Up from UK£13.09, the current price target is an average from 12 analysts. The new target price is 16% below the current share price of UK£16.76. As of last close, the stock is up 37% over the past year. Recent Insider Transactions Derivative • Feb 06
CFO & Director exercised options and sold UK£73k worth of stock On the 3rd of February, Michael Baldock exercised options to acquire 4k shares at no cost and sold these for an average price of UK£16.40 per share. This trade did not impact their existing holding. As of today, Michael currently holds no shares directly. Company insiders have collectively sold UK£260k more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Jan 19
Analysts update estimates The 2021 consensus earning per share (EPS) estimate increased from UK£0.11 to UK£0.13. Revenue estimate for the same period was approximately flat at UK£298.0m. Net income is expected to grow by 139% next year compared to 4.2% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£13.09 to UK£14.00. Share price is up 2.8% to UK£17.13 over the past week. Price Target Changed • Jan 15
Price target raised to UK£14.00 Up from UK£13.06, the current price target is an average from 12 analysts. The new target price is 18% below the current share price of UK£17.04. As of last close, the stock is up 22% over the past year. Is New 90 Day High Low • Jan 13
New 90-day high: UK£16.66 The company is up 29% from its price of UK£12.92 on 14 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£7.26 per share. Major Estimate Revision • Dec 19
Analysts update estimates The 2021 consensus earning per share (EPS) estimate was lowered from UK£0.14 to UK£0.11. No change was made to the revenue estimate which at the last update was UK£297.2m. Net income is expected to grow by 94% next year compared to 4.1% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£12.65 to UK£12.96. Share price is up 1.6% to UK£14.38 over the past week. Recent Insider Transactions Derivative • Nov 05
CEO & Executive Director exercised options and sold UK£291k worth of stock On the 3rd of November, Alan Hirzel exercised options to acquire 19.43k shares at no cost and sold these for an average price of UK£14.99 per share. This trade did not impact their existing holding. For the year to June 2020, Alan's total compensation was 39% salary and 61% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since December 2019, Alan's direct individual holding has increased from 151.13k shares to 180.26k. Company insiders have collectively sold UK£16m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Oct 24
Analysts update estimates The 2021 consensus earning per share (EPS) estimate was lowered from UK£0.14 to UK£0.13. Revenue estimate was approximately flat at UK£296.9m. Net income is expected to grow by 123% next year compared to 11% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target was lowered from UK£12.67 to UK£12.37. Share price is up 9.6% to UK£14.41 over the past week. Is New 90 Day High Low • Oct 22
New 90-day high: UK£14.25 The company is up 8.0% from its price of UK£13.21 on 24 July 2020. The British market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£5.10 per share. Major Estimate Revision • Oct 09
Analysts update estimates The 2021 consensus earning per share (EPS) estimate was lowered from UK£0.16 to UK£0.14. Revenue estimate was approximately flat at UK£298.3m. Net income is expected to grow by 145% next year compared to 9.5% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target was lowered from UK£12.84 to UK£12.67. Share price stayed mostly flat at UK£12.13 over the past week. Reported Earnings • Oct 04
Full year earnings released - EPS UK£0.06 Over the last 12 months the company has reported total profits of UK£12.5m, down 72% from the prior year. Total revenue was UK£260.0m over the last 12 months, largely unchanged from the prior year. Profit margins were 4.8%, which is lower than the 17% margin from last year. The decrease in margin was driven by higher expenses. Major Estimate Revision • Sep 21
Analysts update estimates The 2021 consensus revenue estimate increased from UK£298.3m to UK£301.4m. Earnings per share (EPS) estimate was lowered from UK£0.19 to UK£0.15 for the same period. Net income is expected to grow by 161% next year compared to 12% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£12.62 to UK£12.89. Share price is down by 9.9% to UK£12.45 over the past week.